Association of CYP3A5(*)3, CYP3A4(*)18 & CYP2B6(*)6 polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients

BACKGROUND & OBJECTIVES: Imatinib mesylate (IM) is a reliable first line treatment for chronic myeloid leukaemia (CML). Nevertheless, despite promising results, a considerable proportion of patients develop resistance to the drug. Cytochrome P450 (CYP) enzymes play a crucial role in IM metabolis...

Descripción completa

Detalles Bibliográficos
Autores principales: Asadov, Chingiz, Karimova, Nigar, Hasanova, Aypara, Bayramov, Bayram, Shirinova, Aytan, Alimirzoyeva, Zohra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Practice: Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645035/
https://www.ncbi.nlm.nih.gov/pubmed/37706370
http://dx.doi.org/10.4103/ijmr.ijmr_1103_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645035/
https://www.ncbi.nlm.nih.gov/pubmed/37706370
http://dx.doi.org/10.4103/ijmr.ijmr_1103_22

Ejemplares similares